The assessment of interstitial low-dose rate brachytherapy in localized prostate cancer will be performed by the Institute for Quality and Efficiency in Health Care


Mar 2018

In February, 2018, the Federal Joint Committee (G-BA) has commissioned an assessment of the interstitial low-dose rate (LDR) brachytherapy in localized prostate cancer to the Institute for Quality and Efficiency in Health Care (IQWiG) in order to search, analyze and evaluate the current knowledge on this technology.

The following aspects should be considered for the assessment:

  • Target population: patients in localized prostate cancer (stages for both local and systemic cancer were included);
  • Specification of the method (intervention): treatment with an interstitial low-dose rate (LDR) brachytherapy;
  • Comparative treatments: standard surgical intervention (radical prostatectomy), percutaneous radiotherapy, observational strategies (e.g., active surveillance, watchful waiting);
  • Outcomes (especially patient-relevant outcomes), including mortality, morbidity, quality of life, side effects and complications.

If the relevant economic studies are identified, the information will be sent to G-BA for further evaluation.

The results should be delivered to the G-BA until September, 2018.

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news


May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more


Apr 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2021. Two new EBM codes for IVD tests were introduced, and reimbursement conditions for two IVD tests were amended.

Read more


Apr 2021

According to the available financial results, published by the German Federal Ministry of Health, the German statutory health insurance companies reported a total deficit of around 2.65 billion euros in 2020. The health fund reported a deficit of 3.49 billion euros in 2020. As of January 15, 2021, the health fund's liquidity reserve was around 5.9 billion euros.

Read more


Mar 2021

On March 17, 2021, the Evaluation Committee (Bewertungsausschuss) has decided to introduce two new EBM (German Uniform Evaluation Standard) codes related to prescription of health apps with retrospective effect from January 1, 2021.

Read more


Mar 2021

On March 17, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities. Applicants are invited to submit ideas for projects that fall within one of these funding priorities. The deadline for submitting ideas is June 1, 2021.

Read more